Leerink Partnrs Brokers Increase Earnings Estimates for HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) – Research analysts at Leerink Partnrs upped their Q1 2025 earnings estimates for Hims & Hers Health in a report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $0.11 per share for the quarter, up from their previous forecast of $0.10. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.17 EPS, FY2025 earnings at $0.56 EPS, FY2026 earnings at $0.75 EPS and FY2027 earnings at $1.15 EPS.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million.

HIMS has been the subject of several other reports. Piper Sandler lifted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Bank of America lifted their price objective on Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a report on Thursday, February 20th. Finally, Truist Financial lifted their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $35.71.

Hims & Hers Health Trading Down 1.4 %

NYSE:HIMS opened at $41.30 on Thursday. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98. The company has a market cap of $9.02 billion, a price-to-earnings ratio of 93.85 and a beta of 1.35. The stock has a fifty day simple moving average of $36.19 and a 200-day simple moving average of $26.46.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Crewe Advisors LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. boosted its position in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. boosted its position in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 33,513 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $1,118,296.76. The trade was a 50.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,097,578 shares of company stock worth $38,080,320 over the last quarter. Insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.